Supramolecular Architectures of Meloxicam Carboxylic Acid Cocrystals, a Crystal Engineering Case Study

被引:110
作者
Cheney, Miranda L. [1 ,2 ]
Weyna, David R. [1 ,2 ]
Shan, Ning [1 ]
Hanna, Mazen [1 ]
Wojtas, Lukasz [2 ]
Zaworotko, Michael J. [2 ]
机构
[1] Thar Pharmaceut Inc, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Chem, Tampa, FL 33620 USA
关键词
PHARMACEUTICAL CO-CRYSTALS; PYRIDINE HYDROGEN-BONDS; PHYSICOCHEMICAL PROPERTIES; POSTOPERATIVE PAIN; SALT FORMATION; SYNTHONS; DRUG; SOLUBILITY; FORM; PHARMACOKINETICS;
D O I
10.1021/cg100514g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Meloxicam is a nonsteroidal anti-inflammatory drug with low aqueous solubility and high permeability prescribed for indications of arthritis, primary dysmenorrhea, fever, and pain, in this contribution, we apply crystal engineering and the supramolecular synthon approach to prepare novel meloxicam cocrystal forms with various pharmaceutically acceptable or toxicologically qualified carboxylic acids. As a result, 19 pharmaceutical cocrystals including one cocrystal of a salt are synthesized by solid-state and solution methods. All resulting cocrystals are characterized by X-ray diffraction. infrared. and thermal analyses. In particular, crystal structures of six rneloxicam cocrystals are determined and reported, namely. meloxicam . 1-hydroxy-2-naphthoic acid cocrystal (1), meloxicam . glutaric acid cocrystal (2), meloxicam . L-malic acid cocrystal lit salt (3), meloxicam . salicylic acid cocrystal form 111 (4), meloxicam . fumaric acid cocrystal (5), and meloxicam . succinic acid cocrystal (6). The supramolecular assembly of each cocrystal is analyzed and discussed. It is observed that the meloxicam dimer is robust since this motif is observed in five out of six meloxicam cocrystal structures that have been determined. As part of the continuous development, the resulting meloxicam cocrystal forms will be further investigated to explore improved physicochemical and pharmacological properties.
引用
收藏
页码:4401 / 4413
页数:13
相关论文
共 77 条
[1]   Solid form screening - A review [J].
Aaltonen, Jaakko ;
Alleso, Morten ;
Mirza, Sabiruddin ;
Koradia, Vishal ;
Gordon, Keith C. ;
Rantanen, Jukka .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 71 (01) :23-37
[2]  
Ahmed Mansoor, 2005, Expert Opin Drug Metab Toxicol, V1, P739, DOI 10.1517/17425255.1.4.739
[3]   The Cambridge Structural Database: a quarter of a million crystal structures and rising [J].
Allen, FH .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1) :380-388
[4]  
Allen LV., 2005, ANSELS PHARM DOSAGE, V8th, DOI DOI 10.1177/875512251002600315
[5]   Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].
Almarsson, Ö ;
Zaworotko, MJ .
CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896
[6]  
[Anonymous], 2005, SPECTROSCOPIC IDENTI
[7]   Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities [J].
Banerjee, R ;
Bhatt, PM ;
Ravindra, NV ;
Desiraju, GR .
CRYSTAL GROWTH & DESIGN, 2005, 5 (06) :2299-2309
[8]   Pharmaceutical cocrystal and salts of norfloxacin [J].
Basavoju, Srinivas ;
Bostrom, Dan ;
Velaga, Sitaram P. .
CRYSTAL GROWTH & DESIGN, 2006, 6 (12) :2699-2708
[9]   PHARMACEUTICAL SALTS [J].
BERGE, SM ;
BIGHLEY, LD ;
MONKHOUSE, DC .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1977, 66 (01) :1-19
[10]   Tape and layer structures in cocrystals of some di- and tricarboxylic acids with 4,4′-bipyridines and isonicotinamide.: From binary to ternary cocrystals [J].
Bhogala, BR ;
Basavoju, S ;
Nangia, A .
CRYSTENGCOMM, 2005, 7 :551-562